Exchange: OTC·Updated 03:58 PM EDT

ADAPY Adaptimmune Therapeutics Plc - ADR

$0.0225
$0.0055
(19.64%)
Today
Reported EarningsAug 13
Mkt Cap$7.42M
Vol277,581.00

About ADAPY

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
20

Extremely Bearish Sentiment

How do you feel about ADAPY?

Advertisement|Remove ads.